Cazzamalli Samuele, Corso Alberto Dal, Neri Dario
Department of Chemistry and Applied Biosciences Swiss Federal Institute of Technology (ETH Zurich) Vladimir-Prelog-Weg 4, CH-8093 Zurich.
Department of Chemistry and Applied Biosciences Swiss Federal Institute of Technology (ETH Zurich) Vladimir-Prelog-Weg 4, CH-8093 Zurich;, Email:
Chimia (Aarau). 2017 Oct 25;71(10):712-715. doi: 10.2533/chimia.2017.712.
Cytotoxic drugs, which are commonly used for the pharmacotherapy of many forms of cancer, often cause substantial toxicity to the patient without being able to induce long-lasting remissions. Ligands specific to accessible tumor-associated targets, capable of selective localization at the neoplastic site, may facilitate the preferential delivery of anti-cancer drugs, boosting activity and helping spare normal organs. In this article, we present a critical analysis of the limitation of conventional anti-cancer drugs and we contrast monoclonal antibodies and small organic ligands, as vehicles for pharmacodelivery applications.
细胞毒性药物常用于多种癌症的药物治疗，但往往会给患者带来严重毒性，却无法诱导长期缓解。对可及的肿瘤相关靶点具有特异性的配体，能够选择性地定位于肿瘤部位，可能有助于抗癌药物的优先递送，增强活性并帮助保护正常器官。在本文中，我们对传统抗癌药物的局限性进行了批判性分析，并对比了单克隆抗体和有机小分子配体作为药物递送应用载体的情况。
